This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
Cancer Cell International Open Access 09 October 2021
-
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
Blood Cancer Journal Open Access 21 September 2021
-
Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway
Nature Communications Open Access 23 March 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788–800.
Fisher CL, Randazzo F, Humphries RK, Brock HW . Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family. Gene 2006; 369: 109–118.
Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183–2186.
Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adelaide J et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2009. E-pub ahead of print 29 October 2009; doi:2010.103/leu.2009.2218.
Cho YS, Kim EJ, Park UH, Sin HS, Um SJ . Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem 2006; 281: 17588–17598.
Wang L, Fidler C, Nadig N, Giagounidis A, Della Porta MG, Malcovati L et al. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica 2008; 93: 994–1000.
Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 2000; 19: 3902–3913.
Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006; 108: 337–345.
Lee SW, Cho YS, Na JM, Park UH, Kang M, Kim EJ et al. ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 2010; 285: 18–29.
Acknowledgements
This work was supported by Leukaemia Research of the United Kingdom, and in part by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro) and Fondazione IRCCS Policlinico San Matteo to MC, and by a grant from CajaNavarra Foundation through the Program ‘You choose, you decide’ (Project 10.830) to MFM. We are grateful to the clinicians who have contributed to the clinical assessment of the patients: Dr J Rifón (University Clinic, University of Navarra, Spain), Dr T Carrascosa (Galdakano Hospital, Spain), Dr G Hermida (General Yagüe Hospital, Spain), Dr JJ Hernández-Hernández (San Eloy Hospital, Spain), Dr M Rodríguez-Calvillo (San Miguel Hospital, Spain), Dr A Pereda Vicandi (Santiago Hospital, Spain), Dr MT Ardanaz (Txagorritxu Hospital, Spain), Dr J Feliú (San Millán Hospital, Spain), Dr MC Mateos (Virgen del Camino Hospital, Spain), Dr M Araiz (Nuestra Señora de Aranzazu Hospital, Spain), Dr MA Piñán (Cruces Hospital, Spain) and Dr A Gorosquieta (Hospital of Navarra, Spain).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Boultwood, J., Perry, J., Pellagatti, A. et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24, 1062–1065 (2010). https://doi.org/10.1038/leu.2010.20
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.20
This article is cited by
-
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes
Modern Pathology (2022)
-
Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk
Current Hematologic Malignancy Reports (2022)
-
Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
Cancer Cell International (2021)
-
Roles and mechanisms of BAP1 deubiquitinase in tumor suppression
Cell Death & Differentiation (2021)
-
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
Blood Cancer Journal (2021)